AstraZeneca PLC (AZN) Research

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Market snapshot

Symbol
AZN
Price
$174.93
Day change
-1.66%
Market cap
$271.6B
P/E ratio
25.98x
52-week range
137.22-212.71
Sector
Healthcare
Industry
Drug Manufacturers - General
Next earnings
in 1 month
Analyst price target
$186.67

Recent news

  • The Healthcare M&A Wave

    In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

  • Ozempic Linked To Lower Risk Of Violence In New Study

    The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health, said it is important to continue studying the impact of GLP-1 medications on users' behavior and public safety as the medications become more widespread.

  • AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials

    AstraZeneca Plc (NASDAQ:AZN) is advancing its oral GLP-1 receptor agonist, elecoglipron, into an extensive Phase 3 development program after the drug delivered significant weight-loss and diabetes-control results in two Phase 2b studies.

Peer companies

  • AbbVie Inc. (ABBV)
  • Amgen Inc. (AMGN)
  • Bristol-Myers Squibb Company (BMY)
  • Gilead Sciences, Inc. (GILD)
  • GSK plc (GSK)
  • Johnson & Johnson (JNJ)
  • Eli Lilly and Company (LLY)
  • Merck & Co., Inc. (MRK)

Recent insider activity

  • Sharma Mani — A-Award (1 shares) on 2026-06-08
  • Sharma Mani — S-Sale (11893 shares) on 2026-05-20
  • Sharma Mani — A-Award (1 shares) on 2026-05-06
  • Sharma Mani — A-Award (1 shares) on 2026-04-07
  • Sharma Mani — trade (0 shares) on 2026-03-18

Open AstraZeneca PLC (AZN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.